An RCT, or randomized controlled trial, is a type of scientific study where participants are randomly assigned to different groups to compare the effects of a treatment or intervention. One group receives the treatment being tested while another group receives either a placebo or an existing treatment. Because random assignment makes the groups comparable in every way except the treatment itself, RCTs are considered one of the most reliable ways to determine whether a medical intervention actually works.
How Randomization Works
The defining feature of an RCT is that participants are divided into groups by chance rather than by a doctor’s decision or a patient’s preference. This matters because it means the groups end up similar in age, health status, genetics, and countless other factors that could influence the outcome. If a researcher hand-picked who got which treatment, conscious or unconscious preferences could skew the results. Randomization eliminates that possibility.
There are several ways to randomize. Simple randomization is like flipping a coin for each participant. Block randomization ensures the groups stay roughly equal in size throughout the trial, rather than ending up lopsided by chance. Stratified randomization goes a step further by first sorting participants based on important characteristics (like age or disease severity), then randomizing within each subgroup. This helps guarantee the groups are balanced on factors that could affect the outcome.
Equally important: neither the researchers nor the participants know in advance which group someone will be placed in. This “allocation concealment” prevents anyone from steering certain patients toward a particular group, which would undermine the whole point of randomizing.
What the Control Group Receives
Every RCT has at least two groups. The treatment group gets the intervention being tested. The control group provides the comparison point, and what they receive depends on the situation.
- Placebo control: The control group gets an identical-looking pill, injection, or procedure that contains no active ingredient. This is used when no proven treatment exists for the condition, or when withholding treatment won’t cause serious harm.
- Active control: The control group receives the current best available treatment. This is the standard approach when an effective therapy already exists and it would be unethical to give patients nothing.
- Add-on design: All participants receive standard treatment, but the treatment group also receives the new intervention while the control group gets standard treatment plus a placebo. This way, no one goes without care.
The choice of control group shapes what the trial can prove. A placebo-controlled trial can show whether a treatment works at all. An active-controlled trial shows whether a new treatment is better than, or at least as good as, what’s already available.
Blinding: Who Knows What
To prevent expectations from influencing results, RCTs often use “blinding,” meaning certain people involved in the trial don’t know who’s getting the real treatment. If a patient knows they’re taking a sugar pill, the placebo effect weakens. If a doctor knows which patients are on the experimental drug, they might unconsciously evaluate those patients differently.
In a single-blind trial, the participants don’t know which group they’re in but the researchers do. In a double-blind trial, neither the participants nor the researchers know. Some trials go further, also blinding the people who analyze the data. Interestingly, research has shown that even among scientists, there’s no universal agreement on exactly who “double-blind” covers. A 2020 study in BMJ Open found that authors of published trials gave inconsistent definitions of their own blinding terminology. For this reason, many journals now require researchers to specify exactly who was blinded rather than relying on vague labels.
How RCTs Fit Into Clinical Trial Phases
RCTs are used across different stages of testing a new treatment, and the scale grows dramatically at each phase.
Phase I trials test a treatment in just 20 to 80 people. The goal is basic safety: does this cause harmful side effects? Phase II expands to 100 to 300 people and begins evaluating whether the treatment actually works. Phase III is where the large-scale RCTs happen, enrolling 1,000 to 3,000 participants to confirm effectiveness, compare the treatment against existing options, and monitor side effects thoroughly enough to support regulatory approval. Phase IV trials occur after a drug is already on the market, tracking its safety and performance across the broader population.
Where RCTs Rank in Medical Evidence
Not all research carries equal weight. Scientists use a hierarchy of evidence, often visualized as a pyramid, to rank study designs by reliability. At the bottom sit basic science experiments and case reports. In the middle are observational studies, where researchers watch what happens without assigning treatments. RCTs sit near the top because randomization and controls eliminate many sources of error that weaken other study designs.
Only systematic reviews and meta-analyses rank higher. These are studies that combine the results of multiple RCTs to reach more powerful conclusions. A single RCT can be well-designed yet limited in scope. Pooling many RCTs together provides a broader, more dependable picture.
How Results Are Analyzed
Once a trial ends, how the data gets analyzed matters as much as how the trial was designed. There are two main approaches.
Intention-to-treat analysis counts every participant based on the group they were originally assigned to, even if they stopped taking the medication, switched groups, or dropped out. This mirrors real-world conditions, where patients don’t always follow treatment plans perfectly. Per-protocol analysis only includes participants who completed the study exactly as planned. This reveals how the treatment performs under ideal conditions. Most rigorous trials report both, because together they give a fuller picture of what a treatment can do in practice versus in theory.
The decision about which analysis to use has to be made before the data is collected. Choosing after the fact opens the door to cherry-picking the approach that makes the results look better.
Planning an RCT: Sample Size and Statistics
Before an RCT begins, researchers calculate how many participants they need. Too few, and the trial might miss a real treatment effect. Too many, and it wastes time and resources. This calculation depends on a few key decisions.
The significance level (typically set at 5%) is the acceptable risk of concluding a treatment works when it actually doesn’t. Statistical power (typically set at 80%) is the probability of detecting a real treatment effect if one exists. The expected effect size captures how large a difference between groups the researchers anticipate. A treatment expected to produce a dramatic improvement needs fewer participants to detect than one expected to produce a subtle benefit. These parameters together determine whether a trial of 200 people or 2,000 people is needed.
Strengths and Limitations
The great strength of an RCT is internal validity: the confidence that the observed results reflect the true effect of the treatment rather than some confounding factor. Careful randomization, blinding, and controlled comparisons all work together to minimize bias.
The trade-off is external validity, or generalizability. RCTs use strict eligibility criteria. They often exclude people with multiple health conditions, older adults, pregnant women, or people taking other medications. The participants who qualify may not reflect the full diversity of patients who would use the treatment in everyday practice. A drug that performs well in a tightly controlled trial population might behave differently in a 78-year-old with diabetes and kidney disease.
Researchers can improve generalizability by broadening their inclusion criteria so the study population better resembles real-world patients. But this always involves a balancing act: the more diverse the participants, the harder it becomes to control for all the variables that might influence the outcome. This tension between internal and external validity is a fundamental challenge in clinical research, and it’s why no single RCT, no matter how well designed, is the final word on a treatment.